Table 3.

Trends in the Renal Function in Our Reviewed Patients.

	Case	Age/sex	TAFRO grade	Renal biopsy	RRT duration (day)	AKI improved (day)	AKI recovery definition (#)	Creatinine before the onset of TAFRO syndrome	Creatinine on admission	Max creatinine after treatment	Minimum creatinine after treatment	Creatinine at dischage	AKI to CKD
without critical complications	1	51 F	2	Acute phase	None	10	1	NA	1	1.2	0.6	0.8	Unidentified
	2	38 M	3	No	31	33	2	NA	2.8	5.0	0.8	0.8	Unidentified
	3	85 F	3	No	None	15	1	NA	1.1	1.6	0.8	1.2	Probably yes *
	4	76 F	4	Chronic phase	40	49	2	NA	3.0	6.5	1.4	1.5	Probably yes *
	5	46 M	4	No	None	34	1	NA	0.9	1.5	0.9	0.9	Unidentified
	6	52 F	4	No	13	20	2	NA	1.9	7.2	0.4	0.5	Unidentified
	7	69 M	4	Chronic phase	17	45	2	NA	2.2	4.3	1.2	1.7	Probably yes *
	8	48 F	4	Acute phase	17	21	2	NA	1.3	4.2	0.6	0.6	Unidentified
	9 (Our case)	60 M	5	No	39	39	2	0.8	2.8	10.4	1.1	1.2	Yes
with critical complications	10	68 F	2	No	None	221	1	NA	1.6	1.5	0.7	0.7	Unidentified
	11	17 M	3	No	None	3	1	NA	1.6	2.7	0.6	0.8	Unidentified
	12	72 M	5	No	106	120	2	NA	1.3	6.0	0.9	1.5	Probably yes *
	13	59 M	5	No	19	37	2	NA	1.3	2.2	0.9	1	Unidentified
	14	25 M	5	No	76	76	2	NA	1.0	4.2	0.8	0.8	Unidentified
	15	59 M	5	No	151	228	2	NA	1.4	4.5	0.8	1	Unidentified
					Dialysis duration		Cre on admission		Maximum Cre		Cre at discharge
	All patients				35 [18-67]		1.4 [1.2-2.1]		4.2 [1.9-5.5]		0.9 [0.8-1.2]
	Patients without critical complications median [interquartile range, 25-75%]				24 [17-37]		1.9 [1.1-2.8]		4.3 [1.6-6.5]		0.9 [0.8-1.2]

The cases described as “probably Yes” (*) have no record of creatinine before the onset of TAFRO syndrome. The AKI recovery definition (#) is shown in Fig. 4b.

RRT: renal replacement therapy, AKI: acute kidney injury, CKD: chronic kidney disease, Cre: creatinine